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Abstract
Background. Conventional MRI poorly distinguishes brain parenchyma microscopically invaded by high-grade 
gliomas (HGGs) from the normal brain. By contrast, quantitative histological MRI (hMRI) measures brain micro-
structure in terms of physical MR parameters influenced by histochemical tissue composition. We aimed to deter-
mine the relationship between hMRI parameters in the area surrounding the surgical cavity and the presence of 
HGG recurrence.
Methods. Patients were scanned after surgery with an hMRI multiparameter protocol that allowed for estima-
tions of longitudinal relaxation rate (R1) = 1/T1, effective transverse relaxation rate (R2)*=1/T2*, magnetization 
transfer saturation (MTsat), and proton density. The initial perioperative zone (IPZ) was segmented on the postop-
erative MRI. Once recurrence appeared on conventional MRI, the area of relapsing disease was delineated (exten-
sion zone, EZ). Conventional MRI showing recurrence and hMRI were coregistered, allowing for the extraction of 
parameters R1, R2*, MTsat, and PD in 3 areas: the overlap area between the IPZ and EZ (OZ), the peritumoral brain 
zone, PBZ (PBZ = IPZ – OZ), and the area of recurrence (RZ = EZ – OZ).
Results. Thirty-one patients with HGG who underwent gross-total resection were enrolled. MTsat and R1 were the 
most strongly associated with tumor progression. MTsat was significantly lower in the OZ and RZ, compared to 
PBZ. R1 was significantly lower in RZ compared to PBZ. PD was significantly higher in OZ compared to PBZ, and 
R2* was higher in OZ compared to PBZ or RZ. These changes were detected 4 to 120 weeks before recurrence rec-
ognition on conventional MRI.
Conclusions. HGG recurrence was associated with hMRI parameters’ variation after initial surgery, weeks to 
months before overt recurrence.
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High-grade gliomas (HGGs) are both the most common 
and most malignant primary brain tumors. Despite major 
advances in their treatment and follow-up, the prognosis 
remains poor because of systematic recurrences.1 In addi-
tion to age, risk factors include male sex, previous ionizing 
radiation, white ethnicity, and rare genetic diseases.2 The 
development of glioma is also positively correlated with 
brain size, suggesting that it arises from a stochastic event 
related to the number of cells at risk. When adjusted for 
brain size, the risk of glioma is slightly higher for females.3
The reasons for treatment failure are manifold. First, the 
detection of an HGG comes relatively late in the course of 
its development, either because of its progression from 
a previous lower-grade glioma or to the late outbreak of 
symptoms. However, population-based screening has 
proven neither beneficial nor cost-effective, stressing 
the need for noninvasive methods of early detection.4 
Second, on postmortem examinations, malignant cells 
can be identified far away from the tumor by conventional 
MRI.5,6 Therefore, even when surgery removes all contrast-
enhancing brain tissue and surrounding fluid-attenuated 
inversion recovery (FLAIR) abnormality,7,8 viable tumor 
cells remain in the brain. Various techniques were devel-
oped to alleviate this caveat, to date having some effect 
on outcome: neuro-navigation,9 fluorescence-guided sur-
gery using 5-aminolevulinic acid,10 intraoperative MRI, and 
Raman spectroscopy.11 Third, different radiotherapy regi-
mens are recommended but do not significantly modify 
the outcome.12–14 Finally, the cognitive side effects of brain 
irradiation seem to be dose related.15,16
Thus, novel techniques more sensitive to the presence of 
tumoral tissue than conventional MRI are urgently needed. 
Unfortunately, despite the abundance of novel imaging 
techniques (MR perfusion techniques and analyses of re-
gional cerebral blood volume,17–19 S-transform–based tex-
ture analysis of T1-weighted (T1w) and T2-weighted (T2w) 
images,20 MR spectroscopy,21 apparent diffusion coeffi-
cient,22 chemical exchange saturation transfer,23 dynamic 
contrast-enhanced MRI,24 diffusion tensor imaging25), no 
MR biomarker has so far been able to robustly and accu-
rately predict the localization of HGG recurrence.
Although in vivo brain MRI cannot directly image 
neurons or glial cells, the combination of advanced quan-
titative MRI with biophysical models of MR contrast allows 
one to make inferences about the brain microscopic struc-
ture, thereby approaching in vivo histology MRI (hMRI). 
hMRI has pushed accessible image resolutions into the 
“mesoscopic scale” (0.1  mm-0.5  mm), which comprises 
between macroscopic and microscopic scale, enabling in 
vivo imaging of features including cortical laminae, cortical 
columns, dural lymphatic vessels, and vasculature.26
hMRI harnesses the advantages of quantitative MRI 
methods that measure physical tissue parameters such as 
the longitudinal relaxation rate (R1 = 1/T1), the effective 
transverse relaxation rate (R2* = 1/T2*), the magnetiza-
tion transfer saturation (MTsat), and proton density (PD).
26 
R1 is sensitive to interactions of water molecules with 
other water molecules, water molecules bound to macro-
molecules, and the paramagnetic centers found in cortical 
tissue. R2* is strongly sensitive to paramagnetic iron. The 
MT signal arises from the exchange between fast relaxing 
water bound to macromolecules and slowly relaxing 
unbound water molecules. In consequence, MTsat depends 
strongly on the tissue macromolecular content. PD meas-
ures the free water content of a voxel and decreases with 
the density of MR-invisible macromolecules (eg, lipids and 
proteins).27 Because hMRI is quantitative, the measures 
of physical MR parameters are more reproducible across 
participants and scanners than weighted MRI.28 Currently, 
hMRI has been used to track age-related changes in brain 
microstructure,29 posttraumatic degeneration,30 and al-
terations in normal-appearing gray and white matter of 
patients with multiple sclerosis,31 Alzheimer disease, 
microangiopathy, and paraneoplastic disease.32
Here we capitalized on its high sensitivity to variations 
in brain tissue microstructure to assess, in the postoper-
ative period, whether quantified MR parameters in the 
peritumoral brain zone (PBZ) differed between the regions 
of HGG recurrence and the regions without evidence of 
tumor recurrence.
Methods
The local ethics committee approved this prospective ob-
servational study (B707201316912). Written informed con-
sent was obtained from each patient before inclusion. Data 
acquisition ran from September 2013 to December 2017.
Population
In a single neurosurgical department, all patients with his-
tological diagnosis of HGG (anaplastic astrocytoma [AA], 
anaplastic oligodendroglioma [AO], and glioblastoma 
[GBM]) and gross total resection (GTR) based on imme-
diate postoperative MRI showing no residual enhancing 
tissue were eligible. Exclusion criteria were age younger 
than 18  years, postoperative KPS less than 50, World 
Health Organization performance status greater than 3, 
contraindications to MRI. All patients were discussed in 
multidisciplinary neuro-oncology meetings and treated 
according to European Association for Neuro-Oncology 
(EANO) guidelines.12
Data Acquisition
Patients were asked to participate in the study once the 
diagnosis of HGG was histologically confirmed after sur-
gery. Each patient had standard follow-up MRI every 
3 months. This included T2w, FLAIR, diffusion-weighted im-
aging, and multiplanar 1 mm T1w pregadolinium (pre-Gd) 
and post-Gd contrast-enhanced sequences (Magnetom 
Symphony 1.5T, Magnetom Aera 1.5T, Magnetom Vida 3T 
Siemens Medical Solutions).
A single experimental MRI session was scheduled at 
least 8 weeks (maximum 36 weeks) after surgery to mini-
mize the risks of postoperative artifacts.33 Multiparameter 
quantitative histological MRI (MP-hMRI) data were ac-
quired on a 3T head-only MRI-scanner (Magnetom 
Allegra, Siemens Medical Solutions) or on a 3T whole-
body MRI-scanner (Magnetom Prisma, Siemens Medical 
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a multiparameter mapping protocol, developed in the 
framework of an international collaborative effort in-
cluding several sites.29,34,35 This protocol consists of 3 
colocalized 3-dimensional multiecho fast low angle shot 
(FLASH) acquisitions at 1 × 1 × 1  mm3 resolution and 2 
additional calibration sequences (B1+, B1–) to correct for 
inhomogeneities in the radiofrequency (RF) transmit field. 
The FLASH data sets were acquired with predominantly 
PD, T1, and MT weighting. All 3 had high bandwidth to min-
imize off-resonance and chemical shift artifacts. Volumes 
were acquired in 176 sagittal slices using a 256 × 224-voxel 
matrix. GRAPPA parallel imaging was combined with par-
tial Fourier acquisition to speed up acquisition time in ap-
proximately 20 minutes.
MRI Images Processing
We used SPM 12 (www.fil.ion.ucl.ac.uk/spm) and an 
additional SPM toolbox: (http://hmri.info/) in Matlab 
(Matlab R2015b, The MathWorks Inc) to process the data. 
Quantitative maps were computed from native images 
using the hMRI Toolbox, generating maps of MTsat, effective 
transverse relaxation rate (R2*), longitudinal relaxation 
rate (R1) and PD* maps.36 Briefly, echoes for T1w, PDw, and 
MTw were extrapolated to echo time (TE) = 0 to increase 
the signal-to-noise ratio and suppress the R2* bias.37,38 
The resulting MTw and T1w (TE = 0) images were used to 
calculate MTsat and R1 maps. Quantitative R1 and MTsat 
maps were corrected for local RF transmit field inhomoge-
neity and imperfect RF spoiling with the 2 aforementioned 
(B1+, B1–) calibration sequences.39,40 MTsat measures the 
percentage loss of magnetization resulting from the MT 
prepulse used. MTsat differs from the commonly used MT 
ratio (MTR) by explicitly accounting for spatially varying 
T1 relaxation time and flip angles. The MTsat map shows a 
better contrast-to-noise ratio than the MTR.41 Quantitative 
R2* was estimated from all 3 multiecho series (PDw, MTw, 
and T1w) using the ESTATICS model.37
Based on the T1w maps acquired in the MP-hMRI pro-
tocol, we manually delineated a region of interest (ROI) of 
brain tissue with abnormal appearance on T1 and R2* im-
ages around the surgical cavity called the initial periopera-
tive zone (IPZ). This ROI is presumably composed of brain 
parenchyma, edema, and tumor infiltration and corres-
ponds to FLAIR abnormality around the cavity.13
Based on the first follow-up clinical MRI that showed 
tumor progression on T1 + Gd, we manually delineated a 
second ROI that corresponded to the contrast-enhancing 
signal of the recurrent disease (extension zone, EZ). Patients 
who could be reoperated on and in whom recurrence was 
histologically confirmed (ruling out pseudoprogression or 
radionecrosis) were also included in the study. The deline-
ation of abnormal-appearing brain parenchyma and ROIs 
was performed by a senior neurosurgeon with more than 
10  years’ experience in neurosurgery (G.R.) and double-
checked by a senior neurologist with more than 30 years’ 
experience in computational neuroimaging (P.M.).
The 4 parametric maps (MTsat, R1, R2*, and PD), the 
3-dimensional-T1Gd (recurrence MRI), and the corre-
sponding ROIs were coregistered using a rigid-body 
transform and normalized mutual information approach.42 
From these, we identified the area of overlap (overlap 
zone, OZ) between the IPZ and EZ. We also defined the re-
currence zone (RZ; ie, EZ – OZ). The PBZ was defined as a 
FLAIR abnormality without evidence of tumor recurrence 
(PBZ = IPZ – EZ) (Figure 1).
Voxel values of MTsat, R1, R2*, and PD were extracted 
from the corresponding coregistered parametric map in 
PBZ and RZ (see Figure 1). From these, we computed the 
mean voxel values in the area of overlap between the 2 
ROIs (OZ), as well as the mean value of the initial PBZ 
and RZ (this time after exclusion of their overlap). This 
system provided 3 areas of interest (initial PBZ, RZ, and 
OZ) and 4 tissue parameters (MTsat, R1, R2*, and PD) in 
the ipsilateral part of the brain. Statistical analyses were 
all performed using Jamovi software (The jamovi project 
[2019]. jamovi. [version 1.1.9] [computer software]; 
https://www.jamovi.org). First, we proceeded to a mixed 
analysis of variance (ANOVA) with ROIs (PBZ vs RZ vs 
OZ) as repeated measures and the scanner as between-
subject variable on the median value of each parameter. 
In case of sphericity violation identified by the Mauchly 
test, we applied the Greenhouse-Geisser correction. 
Partial eta squared (η) was used as a measure of effect 
size. In case of significant main effect or interaction, we 
performed the Tukey honestly significant difference post 
hoc test to account for multiple comparisons across 3 
areas (peritumoral vs overlap, overlap vs recurrence, 
peritumoral vs recurrence), see Supplementary mate-
rial. Second, we compared the median value between 
the abnormal-appearing white matter ROI and the recur-
rence ROI for each parameter using a mixed ANOVA with 
ROIs (PBZ vs RZ) as repeated measures and the scanner 
as between-subject variable to include patients in whom 
recurrence was not located in the abnormal-appearing 
white matter ROI (n = 3). To confirm the equivalence be-
tween both scanners, we performed a 2 one-sided equiv-
alence test (TOST). Finally, multiple linear regression 
analyses were conducted to explain progression-free 
(PFS) and overall survival by the 4 tissue parameters 
(MTsat, R1, R2*, and PD) in the PBZ and RZ areas.
Results
Demographics
Thirty-one patients were included in the study. Two patients 
who had interrupted MRI follow-up or died before fol-
low-up showed recurrent contrast enhancement. Among 
the 29 patients who showed recurrent contrast enhance-
ment suggesting HGG recurrence, 22 showed clinical and 
radiological progression despite steroid administration. In 
7 patients, pseudoprogression or radionecrosis were diag-
nosed, based on diffusion imaging, perfusion imaging, 
and [18F]-fluoro-deoxyglucose PET criteria.43 Among the 
22 patients who showed clear recurrence, we found an 
overlap between the IPZ ROI and the recurrence ROI in 19 
cases. In 3 cases, recurrence was located outside this area. 
The delays between the initial resection and the MP-hMRI 
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From initial resection to the MP-hMRI, all patients received 
radiation therapy. A  small variation in radiation regimen 
must be mentioned: 60 Gy in 30 fractions was delivered 
for GBM, and a dose of 59.4 Gy in 33 fractions was given 
for AAs and AOs. GBM patients received concomitant 
temozolomide during that phase.
After MP-hMRI, all patients followed adjuvant treatment 
according to EANO guidelines.12 GBM and AA patients re-
ceived temozolomide after irradiation and AO patients re-
ceived PCV (procarbazine, lomustine, and vincristine) after 
irradiation.
The MP-hMRI was acquired during the adjuvant treat-
ment phase, during the time window between concom-
itant radiochemotherapy and chemotherapy alone. We 
considered that early postoperative changes could flaw 
data from the peritumoral zone during the first postop-
erative weeks. Indeed, diffusion studies reported that 
values were modified in the peritumoral zone right 
after surgery.44,45 Likewise, radiation therapy also can 
induce posttreatment modifications although they typ-
ically occur several weeks to months after the end of 
irradiation.46
The outlier patient for whom acquisition was delayed 
(36 weeks) was a patient who was misdiagnosed with low-
grade glioma and then reclassified as isocitrate dehydro-
genase wild-type GBM (IDHWT-GBM) and was therefore 
offered adjuvant therapy.
The delay between the initial MP-hMRI acquisition and 
the follow-up MRI showing a recurrence ranged from 4 to 
120 weeks (median, 36 weeks). After surgery, each patient 
had a standard follow-up MRI every 3 months or earlier in 
case of clinical deterioration as recommended by EANO 
guidelines.47 For the comparison between MP-hMRI and 
follow-up MRI, we considered only the first follow-up MRI 
that showed clear recurrence. This time frame of 4 to 120 
weeks between MP-hMRI and recurrence MRI corresponds 
to a PFS of 12 to 156 weeks, which is in line with current 
literature results for a sample of 22 GBMs, 5 AAs, and 4 
AOs.48,49
Histology at inclusion was AA (n = 5), AO (n = 4), and 
GBM (n = 22). Mean PFS was 52 weeks (range, 12-156 
weeks) (Figure 2; Table 1 and Supplementary material).
Statistical Results
The mixed ANOVAs showed a main effect of the ROIs on 
each parameter (for MTsat: [F(2,34) = 8.76, P < .001, =0.34], 
for PD: [F(2,34) = 4.20, P = .02, =0.20], for R1: [F(2,34) = 7.68, 
P = .002, =0.31], and for R2*: [F(1.51,25.70) = 4.84, P = .02, 
=0.22)] (Figures  3 and 4). The post hoc test revealed a 
higher mean value of MTsat parameter in the PBZ com-
pared to the OZ (P = .03) and the RZ (P < .001), and the RZ 
























Figure 1. Diagram of the different coregistered regions of interest. A, *Corresponds to the surgical cavity. Initial perioperative zone (IPZ) cor-
responds to initial postoperative fluid-attenuated inversion recovery (FLAIR) abnormality. Extension zone (EZ) corresponds to later gadolinium-
enhanced progression. Overlap zone (OZ) is the overlap between IPZ and EZ. Recurrence zone (RZ) corresponds to gadolinium-enhanced 
progression outside the initial FLAIR abnormality (RZ = EZ-OZ). Peritumoral brain zone (PBZ) corresponds to the initial FLAIR abnormality outside 
the EZ. (PBZ = IPZ – EZ). B, Postoperative histological MRI (hMRI) and follow-up conventional T1-weighted MRI + gadolinium are automatically 








niversity of Liege user on 15 D
ecem
ber 2020
 650 Reuter et al. Quantitative hMRI as a biomarker of HGG progression
value of the PD parameter is lower in the PBZ than in the 
OZ (P = .03), whereas there was no significant difference 
between the other comparisons (PBZ vs RZ: P = .07, RZ vs 
OZ, P = .92). The mean value of the R1 parameter is higher 
in the PBZ than in the RZ (P = .001), whereas there was 
no difference between the other comparisons (PBZ vs 
OZ: P = .23, RZ vs OZ, P = .08). Finally, the mean value of 
the R2* parameter is higher in the OZ compared to the 
PBZ (P = .05) and RZ (P = .02), which did not differ from 
each other (P = .90). We found no significant main effect 
of the scanner (Magnetom Allegra vs Magnetom Prisma, 
all P > .16) nor an interaction between the scanner and re-
peated measures (all P > .09).
We also performed a mixed ANOVA including the 
patients for whom the recurrence was located away 
from the abnormal-appearing white matter, with no 
contact with the vicinity of the surgical cavity. MTsat 
(F[1,20] = 9.49, P = .006, =0.32) and R1 (F[1,20] = 7.49, 
P = .01, =0.27) parameters were again significantly 
lower in the RZ than in the PBZ, whereas the difference 
was not significant for the other parameters (for PD: 
F[1,20] = 2.76, P = .11, =0.12, R2*: F[1,20] = 0.18, P = .68, 
=0.01). We found no significant main effect of the scanner 
(all P > .16) nor a interaction between the scanner and re-
peated measures (all P > .19).
We conducted a TOST equivalence test for each pa-
rameter to compare scanner 1 vs scanner 2 data (see 
Supplementary material). This test showed no statistical 
difference between both scanners for all parameters (MT 
P = .474, R1 P = .693, R2* P = .450, PD P = .145) and showed 
equivalence for all parameters for both scanners (MT: 
PUpper = .029, PLower = .002, R1: PUpper = .007, PLower = .002, R2* 
PUpper = .002, PLower = .047, PD PUpper = .050, and PLower < .001.
Finally, the parameter in the PBZ and RZ did not statisti-
cally explain PFS (F[8,13] = 0.45, P = .87, R2 = 0.22) nor OS 
(F[8,13] = 1.27, P = .34, R2 = 0.44).
Discussion
The main result of this prospective study is that quantita-
tive MR parameters differ within the initial perioperative 
area between the region where HGG will subsequently 
recur (OZ and RZ) and the area where it will not (PBZ). 
These differences in brain microstructure, characterized 
by a decrease in MTsat and an increase PD in OZ and a 
sharper fall of MTsat and R1 in RZ, antedate by weeks the 
recurrence visible on conventional MRI. This suggests that 
they result from microstructural modifications induced by 
infiltrating tumor tissue, macroscopically undetectable by 
intraoperative inspection or conventional MRI.
Little is known about the microstructural changes as-
sociated with occult tumor invasion. Preoperatively, 
R1 and R2* decrease with increasing distance from the 
contrast-enhancing part of the tumor.50 Within the pre-
operative peritumoral FLAIR hypersignal, a bimodal 
pattern of relaxation values suggested a distinction be-
tween peritumoral edema (high R1) and nonenhancing 
infiltrating tumor (low R1).50 T1 was shown to be pro-
longed (ie, R1 shortened) before any change was de-
tectable by conventional MR in the peritumoral brain of 
6 patients with recurrent GBM under bevacizumab, sug-














Figure 2. Population Samples.
  
  
Table 1. Study Population Data n = 29 (Study Dropouts Excluded)
Age, y Min 17, max 75, median 52.5, mean 
49.34
Sex Female n = 6, male n = 23
Diagnosis at inclusion Anaplastic astrocytoma n = 5 (17.2%), 
anaplastic oligodendroglioma n = 4 
(13.8%), glioblastoma n = 22 (75.9%)
Epilepsy during 
follow-up 
n = 14 (48%)
Motor deficit at 
diagnosis
n = 8 (27.5%)
Maximal size in 
T1 + Gd at diagnosis, 
mm
Min 0, max 80.6, mean 41.03, median 
40
Maximal size in T2 at 
diagnosis, mm
Min 20.7, max 126, mean 67.9, me-
dian 70
Location Frontal n = 12 (41.3%), temporal 
n = 8 (27.5%), temporoparietal n = 2 
(6.8%), occipital n = 1 (3.4%), central 
n = 4 (13.8%), insular n = 2 (6.8%)




n = 16 (55%)
IDH-1 mutation Negative n = 15 (51.7%), positive 
n = 9 (31%), unknown n = 3 (10.3%)
Operative 
complications
1 meningitis, 2 intratumoral 
bleedings
Abbreviations: Gd, gadolinium; IDH-1, isocitrate dehydrogenase 1; 
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Figure 4. Mean values and SDs of the quantitative parameters inside each relevant region of interest (ROI). R1, longitudinal relaxation rate; R2, 
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Figure 3. Parameters distribution. Violin diagrams of the parameters in the peritumoral brain zone, overlap zone, recurrence zone, and contra-
lateral hemisphere. Ipsilateral statistically significant differences are displayed for each parameter. MT, magnetization transfer. OZ, overlap zone; 
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hMRI in 13 GBMs found that the MTR was lower in the 
tumor area compared to the contralateral hemisphere.52 
These results agree with the current postoperative find-
ings of lower MTsat and R1 in the area where the HGG will 
recur (Figure 5).
The histological underpinning of the changes in quanti-
tative parameters remains uncertain. In this study, PD was 
higher in the OZ compared to the PBZ. Blystad et al50 also 
found a bimodal distribution of PD values in a peritumoral 
edema with high values associated with infiltration and 
low values associated with edema. Here, we included 
patients only after surgery, when very little edema is ob-
served. Therefore, we hypothesize that high PD values are 
correlated with tumor infiltration.
MTsat, a parameter strongly related to myelin content,
53,54 
is robustly decreased in the OZ and even more so in the RZ 
compared to PBZ. During the invasion phase, glioma cells 
produce matrix metalloproteinases that degrade extracel-
lular matrix (ECM) components and allow remodeling of 
the ECM around blood vessels or white-matter tracts. It is 
tempting to suggest that MTsat is correlated to ECM integ-
rity and that glioma extension, inducing ECM destruction, 
would result in MTsat diminution along the way of glioma 
progression.
R1, the longitudinal relaxation rate (R1 = 1/T1), is influ-
enced by different factors: water content, iron concentra-
tion, and coherence of macromolecules, such as myelin.55 
In this study, R1 was significantly lower in the OZ and RZ 
compared to the PBZ. R1 was even lower in the RZ than 
the OZ. ECM contents might be destroyed along the way of 
glioma invasion and it has also been recently understood 
that iron avidity is enhanced in HGG because of inflamma-
tion.56,57 R1 decreases as glioma invades brain tissue but 
may increase as a result of iron avidity in the proliferating/
necrotic core. These 2 phenomena therefore act competi-
tively on R1 value. The R1 value will be only slightly af-
fected where ECM is destroyed and necrosis present (low 
R1 in the OZ) and more affected where ECM is destroyed 
but necrosis/inflammation is absent (lower R1 in the RZ). 
By contrast, R1 was significantly lower in the PBZ com-
pared to the contralateral hemisphere, suggesting that 
the most important modification of the R1 parameter was 
due to tumor infiltration (low R1) and not edema (high R1). 
Also, MT and R1 tend to decrease with aging, especially 
in white matter; 29 we report within-subjects results only, 
which rules out any age effect.
R2*, the effective transverse relaxation rate (1/T2*), is af-
fected by nonheme iron, mainly found in oligodendrocytes 
and myelin,58 but also by myelin content, fiber orientation, 
and water content. We also found that R2* was lower in the 
RZ compared to the OZ (P = .02); we interpret this result 
as, in the whole recurrence, a high R2* correlates with an 
increase in iron content in the most aggressive part of the 
tumor. Also, R2* was significantly lower in the PBZ than 
in the contralateral hemisphere. Mehrabian and colleagues 
have found that in white matter contralateral to the tumor, 
the T2 signal tends to be higher (lower R2) than in the white 
matter of healthy controls,52 suggesting that relaxometric 
parameters are already modified in a normal-appearing 
hemisphere. In line with these results, here we found that 
R2* was lower in the PBZ compared to the contralateral 
hemisphere.
Finally, MT in the tumor before surgery, inferred from 
chemical exchange saturation transfer MRI, was found 
by Regnery et al to be significantly lower in patients with 
GBM in whom the tumor will progress earlier than in those 
in whom GBM will progress slowly (ie, stable disease).23 
The authors found a significant relationship between MTR 
and PFS. This was not the case in the present investigation. 
The cause of this discrepancy might first be related to the 
population. In this study, we included grade 3 tumors and 
GBMs, whereas Regnery and colleagues exclusively in-
cluded GBMs. Because GBM has a more destructive pat-
tern, we could expect that this difference might partially be 
  









Figure 5. Exemplative case of a patient with glioblastoma before recurrence was noted. T1 + gadolinium on the left; magnetization transfer sat-
uration (MTsat) and longitudinal relaxation rate (R1) were acquired at the same time. MTsat and R1 show a clear decrease where recurrence will 
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related to that destructive effect of GBM on MT. Second, 
Regnery et al predicted PFS on the basis of an MRI before 
any surgical treatment, at which time the tumoral burden is 
higher than after surgery. Here, we included patients only 
after GTR, based on postoperative T1 + Gd. We suppose 
that MT variation is subtler than before surgery and there-
fore we cannot reject the null hypothesis where there is no 
relationship between PFS/overall survival and the hMRI 
parameters.
Limitations of the Study
HGG is a genetically and radiologically heterogeneous dis-
ease.59 We report a mean PFS of 52 weeks (range, 12-156 
weeks), in line with current results in HGG treatment.60 
Nevertheless, considering that 75.6% of the tumors were 
GBMs, mean PFS is relatively good and might suggest 
a selection bias (inclusion of only GTRs, good KPS, for 
example).
The second limitation is related to a relatively small 
sample size. The present results cannot be generalized to all 
HGG, nor be used to predict individual patient outcomes.
The third limitation arises from the cross-sectional de-
sign. We acquired MP-hMRI in the postoperative phase 
only. Although presurgical evaluation would have been 
interesting, reliability overcoming postoperative brain 
shift during coregistration of initial and recurrence MRI 
scans remains a challenge.61 The present study design 
compared postoperative MRIs and was thus less prone 
to brain shifts, although recurrence can itself result in 
spatial changes, and postoperative MRI artifacts can 
be due to blood clots, skin staples, and early postoper-
ative vascular changes.13 Eight weeks was considered 
the minimal period for postoperative modifications to 
disappear.
Future investigations should assess the time course of 
hMRI changes after initial surgery through longitudinal re-
peated hMRI, with the goal of determining thresholds of 
parameters variation suggestive of tumor infiltration.
Finally, different MR scanners were used for conven-
tional follow-up and experimental MRI. Nevertheless, 
MP-hMRI is especially dedicated to be interchangeable 
between scanners and locations and has proven to give 
similar results whatever the scanner36 (see Supplementary 
material). This is the first paper describing the use of 
hMRI in glioma patients; therefore, we acknowledge that 
the interval (Δ Lower – Δ Upper) we selected for the TOST is 
somewhat arbitrary. To properly define this interval, a 
comparison study between hMRI parameters and surgical 
sample histology will be carried out if the ongoing replica-
tion study confirms the importance of hMRI in recurrence 
prediction.
Conclusions
HGG treatment failure is partly explained by relatively 
imprecise radiological evaluation of brain parenchyma 
microinvasion. The development of new MRI biomarkers 
indicating brain microinvasion could lead to tailored sur-
gical and radiation therapy treatment, with the goal of 
better survival and fewer neurological and cognitive side 
effects. This study shows a distinct pattern of MP quan-
titative MRI values in the area of the recurrence long be-
fore the recurrence is clinically and radiologically evident 
on conventional MRI. This study thus confirms that pres-
ently radiologically occult modifications occur in the cere-
bral microstructure while the brain is being invaded and 
that these modifications can be detected. If replicated on 
a larger scale, MP MR values could be used as MRI bio-
markers of tumor progression and to target treatments.
Supplementary material
Supplementary material is available online at Neuro-
Oncology Practice (http://nop.oxfordjournals.org/).
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